Form 8-K - Current report:
SEC Accession No. 0001193125-25-002165
Filing Date
2025-01-06
Accepted
2025-01-06 16:10:52
Documents
13
Period of Report
2025-01-06
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K d909597d8k.htm   iXBRL 8-K 27125
  Complete submission text file 0001193125-25-002165.txt   153166

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250106.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250106_lab.xml EX-101.LAB 18756
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250106_pre.xml EX-101.PRE 11699
15 EXTRACTED XBRL INSTANCE DOCUMENT d909597d8k_htm.xml XML 3782
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25511179
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)